Genmab — Januar 2026

[Plimsoller]

*nede

[w]

2080

[KWC]

Forventet ... Takker

[JKY_VH]

Ja, det svarer meget godt til luk i US i fredags

[E_L]

SHB: Överdriven marknadsreaktion på Genmabs Epkinly-studie https://borsvarlden.com/artiklar/shb-overdriven-marknadsreaktion-pa-genmabs-epkinly-studie

[NiklasZ]

Lige ned og kysse trendlinjen.

[E_L]

let's hope it's only a quick kiss on the cheek to say a final goodbye before taking off again...

[ProinvestorNEWS]

Genmabs kursklø efter nye data er overdreven mener Handelsbanken https://proinvestor.com/investornyt/1404483/genmabs-kursklo-efter-nye-data-er-overdreven-mener-handelsbanken

[nohope]

Det er jeg ikke enig i, det er dårligt varsel for de resultater, der kommer senere i år.

[E_L]

why do you think that?
they are all combination trials, and they have PFS as Primary Outcome Measure (OS Secondary )

[StockBull]

Ser ud til kurs 2000 holder - valgt at genkøbe lidt i 2050.

[Darvin]

I completely agree E L

[E_L]

in separate news, the AbbVie trial is on hold for now, until final resolution of the related U.S. International Trade Commission (ITC) investigation https://www.pacermonitor.com/public/case/57357486/AbbVie_Inc_v_Genmab_AS_et_al

[StockBull]

Kursen skulle omkring 2020 holde nogenlunde heroppe, hvis den ikke skulle ryge ud gennem bunden i trendkanalen fra september. Et luk under 2000 åbner døren ned mod 1850.

[StockBull]

Det potentielle kurstarget 2500–2600 i april? Skal revurderes – rejsen ser ud til at blive noget længere.

[E_L]

Xian Deng
UBS
Buy Kr.2,750.00 Maintained Today

[gentogen]

Hvis man ikke har fulgt med i, hvad kombinationsbehandlingerne har vist, så kan dette link anbefales. https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-multiple-clinical-trials-showing-treatment

[E_L]

Analyst Charlie Haywood from Bank of America Securities reiterated a Buy rating on Genmab A/S and increased the price target to DKK2,500.00 from DKK2,250.00 https://www.tipranks.com/news/ratings/maintaining-buy-on-genmab-epkinly-combination-potential-outweighs-monotherapy-setback-ratings

[E_L]

While the Epkinly Phase III monotherapy study in second-line DLBCL failed to show an overall survival benefit, Haywood views this as a relatively minor financial issue, representing only a small fraction of his valuation. He emphasizes that the most significant value drivers are the first- and second-line combination trials, which target the vast majority of the DLBCL population and have progression-free survival as their main endpoint, an outcome measure already supported by encouraging prior

[E_L]

data. He also notes that the missed monotherapy trial does not materially alter the investment case because Genmab’s strategy has always been more focused on combinations, where early-stage results have been notably stronger.